Phase II study of Neoadjuvant Letrozole and Docetaxel for Postmenopausal, Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-05)
Phase 2
- Conditions
- Postmenopausal, hormone-receptor positive and primary breast cancer
- Registration Number
- JPRN-UMIN000001214
- Lead Sponsor
- Japan Breast Cancer Research Group (JBCRG)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1. Unmanageable serious complications 2. HCV 3. Unmanageable diabetes 4. Suspicious infection with fever 5. Active double cancer 6. Neuropathy 7. Edema 8. Inflammatory breast cancer 9. Bilateral breast cancer 10. History of drug-hypersensitivity 11. Under treatment of continuous systematic steroids, estrogen and raloxifene 12. Serious mental disease 13. Patient judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method